Navigation Links
deCODE Discovers Four New Risk Factors for Prostate Cancer
Date:9/20/2009

REYKJAVIK, Iceland, September 20 /PRNewswire-FirstCall/ --

- Findings Further Increase Power of DNA-Based Testing to Identify Men at Substantially Increased Risk, and Will be Integrated Into the deCODE ProstateCancer(TM) Test

deCODE genetics (Nasdaq: DCGN) today announced that a team of its scientists and academic colleagues from Finland, Spain, the Netherlands and the United States have today published the discovery of four novel single-letter variations in the sequence of the human genome (SNPs) conferring increased risk of prostate cancer. This is the sixth set of risk factors for prostate cancer that deCODE has found. The SNPs are located on chromosomes 3q21, 19q13, as well as on 8q24, a region of the genome where deCODE and others have previously discovered risk factors for prostate, breast, colon and bladder cancer. The deCODE team followed up these latest findings with a population-based analysis in Iceland of these and other published sequence variants linked to risk of prostate cancer. This analysis demonstrates that by testing for these published SNPs it is possible to identify the approximately 1.5% of men who are at more than 2.5 times the average risk of the disease.

"With these latest findings we continue to extend our understanding of the genetic risk factors for prostate cancer, the second most common cause of cancer deaths in men. Using our ability to put these SNPs in a population-wide context, we show that it is now possible to identify those who are at more than 30% lifetime risk, independent of other standard risk factors such as age and family history. By incorporating this new, personalized gauge of susceptibility into our arsenal for improving prevention and early diagnosis, we can more effectively and accurately identify those men who would benefit most from intensive screening. We are pleased to be incorporating these latest markers into our deCODE ProstateCancer(TM) test," said Kari Stefansson, CEO of deCODE.

Today's findings result from the analysis of several large datasets: deCODE's genome-wide SNP data from tens of thousands of patients and healthy controls from Iceland; sequencing data from regions in the genome where deCODE and others have already discovered prostate cancer risk factors; and publicly available data from other case-control cohorts from the US, France and Finland. Data from a combined total of more than 60,000 patients and healthy control subjects were included in the study.

The paper, 'Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility,' is published today in the online edition of Nature Genetics, at http://www.nature.com/ng.

Acknowledgements

deCODE wishes to thank the patients and control subjects from many countries whose participation made this work possible. This study was funded in part by the European Union's PROMARK and CancerGene grants to deCODE; by the US Department of Veterans Affairs, and by the Academy of Finland, Sigrid Juselius Foundation, Finnish Cancer Organizations, and Pirkanmaa Hospital.

About deCODE

deCODE is a global leader in analysing and understanding the human genome. The company has identified key variations in the sequence of the genome conferring increased risk of major public health challenges from cardiovascular disease to cancer, and employs its gene discovery engine to develop DNA-based tests to assess individual risk of common diseases; to license its tests and intellectual property to partners; and to provide comprehensive, leading- edge contract services to companies and research institutions around the globe. Through its CLIA- and CAP-certified laboratory deCODE offers a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. Through its pioneering personal genome analysis service deCODEme(TM), the company enables individuals to better understand their risk of dozens of common diseases and to learn about their ancestry and other traits. Through its chemistry and biology units deCODE has also developed a therapeutic product portfolio, which includes DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051, a compound targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer's disease and other conditions. The company intends to partner or directly outlicense these programs. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at http://www.decode.com; at http://www.decodediagnostics.com; at http://www.decodeme.com; and on our blog at http://www.decodeyou.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the effect of a potential delisting of our common stock from The Nasdaq Global Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

    Contacts:

    deCODE genetics
    Edward Farmer
    +354-570-1900
    edward.farmer@decode.is

    Joy Bessenger
    +1-212-481-3891
    joy.bessenger@decode.is

    Gisli Arnason
    +354-570-1900
    gisli.arnason@decode.is


'/>"/>
SOURCE DeCODE Genetics Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke
2. deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia
3. deCODE Receives California Clinical Laboratory License
4. deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
5. A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
6. Major deCODE-led Study Underscores Role of the Brain in Obesity
7. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
8. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
9. deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
10. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
11. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... , July 14, 2017 Endo International plc (NASDAQ: ... on Tuesday, August 8, 2017.  Members of its senior management team ... markets open at 8:30 a.m. ET. The dial-in ... (866) 497-0462, International (678) 509-7598, and the passcode is 45397076. Please ... A replay of the call ...
(Date:7/12/2017)... July 12, 2017 CarpalAID is a revolutionary new product ... surgery. Carpal tunnel syndrome affects more than 8 million ... the rate of men. The common methods of treating CTS are ... uncomfortable hand braces or gloves. ... CarpalAID is a clear patch worn on ...
(Date:7/11/2017)... LINCOLNSHIRE, Ill. , July 11, 2017 /PRNewswire/ ... hematology and urinalysis diagnostic testing equipment as well ... latest innovation: a way to make quality assurance ... control processes. "Sysmex is well known for the ... SM Quality Monitor elevates quality assurance processes ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... 24, 2017 , ... The 2017 NCSL International Workshop & ... focuses on the new ISO/IEC 17025 standards. This marks the first time in ... calibration will be changed. , As an exhibitor, METTLER TOLEDO will showcase ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking ... shows that adherence rates for positive airway pressure (PAP) therapy, the most widely ...
(Date:7/24/2017)... ... July 24, 2017 , ... A Southern California-based author has released ... abuse, and how she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle ... how she has risen above. , In “Memories,” readers get a firsthand look at ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to eliminating clubfoot as ... 100,000 children in their treatment program. Clubfoot is a pervasive problem in the ... is limited or non-existent. Without intervention, these children are destined to grow up ...
(Date:7/24/2017)... ... July 24, 2017 , ... Clinical Quality Assurance:, Roles and ... 22-23, 2017 – Arlington, VA, http://www.fdanews.com/cqa , Early bird pricing for ... growing demands to track and report adverse events place even greater pressure on ...
Breaking Medicine News(10 mins):